本研究正在测试一种使用质子治疗（PT）的较短程前列腺癌治疗方法，质子治疗非常精准，与传统放射治疗相比可能引起较少副作用。然而，其费用昂贵且许多患者难以获得。为使其更可负担及更易获得，本研究正在测试2次分次的立体定向身体质子治疗（SBPT）能否与标准5次治疗同样安全有效。
适应症：Prostate Cancer Patients Treated by Radiotherapy
入组条件
纳入标准
- Men aged \< 18 years with histologically confirmed low- or intermediate-risk prostate cancer per NCCN guidelines
- Eastern Cooperative Oncology Group (ECOG) performance status \<2
- Ability to undergo magnetic resonance imaging (MRI) simulation scans without absolute contraindications, such as cardiac implantable electronic devices
- Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire
排除标准
- History of inflammatory bowel disease or other cancers (except prostate cancer)
- Prior pelvic radiotherapy, chemotherapy, radical prostatectomy, cryosurgery, or focal therapy (e.g. high-intensity focused ultrasound \[HIFU\]) for prostate cancer
- History of bladder neck or urethral stricture
- Transurethral resection of the prostate (TURP) \< 8 weeks prior to SBPT
- Prostate volume \> 100cc on MRI
- Unilateral or bilateral hip replacements
- Nodal or distant metastases, as indicated by computed tomography (CT), MRI, or prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scans
- Previous androgen deprivation therapy (ADT) lasting more than 6 months
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。